The short answer: Prolia has not been shown to cause cancer, but the question comes up because of how the drug works and some patterns in clinical trials

Prolia (denosumab) is a bone-strengthening injection used to treat osteoporosis and prevent fractures. It works by slowing the cells that break down bone. The drug does not directly damage DNA or trigger the cellular changes that start cancer. However, because Prolia affects the immune system in specific ways, researchers have looked carefully at whether it might increase cancer risk—and the evidence so far does not show that it does.

The concern is not unfounded. Any drug that alters immune function deserves scrutiny. But after more than a decade of use and millions of doses given, the pattern in the data does not point to a cancer link. What matters for your own situation is understanding what the research actually found, what remains uncertain, and what to watch for.

Key Takeaways

  • Prolia does not damage DNA directly and has not been shown to increase cancer risk in large clinical trials or in real-world use over many years.
  • The drug works by blocking a protein that helps immune cells survive, which raised theoretical concerns that were then tested in actual patients.
  • Some cancers appeared slightly more often in Prolia users in trials, but the numbers were small and could have occurred by chance.
  • Your individual risk depends on your age, medical history, and other medications—not on Prolia alone.
  • If you take Prolia, routine cancer screening appropriate for your age remains the standard approach.

How Prolia affects the immune system and why researchers looked for a cancer link

Prolia works by blocking RANKL, a protein that helps certain immune cells (called osteoclasts) survive and function. These cells normally break down old bone so new bone can form. By blocking RANKL, Prolia slows bone loss and strengthens bones—which is why it works for osteoporosis.

The concern arose because RANKL also plays a role in the broader immune system. When you block it, you are changing how some immune cells behave. In theory, a weakened immune response could allow cancer cells to grow unchecked. This is not speculation—it is a reasonable hypothesis that warranted testing. So researchers looked at whether people taking Prolia actually developed cancer more often than people who did not.

What they found was reassuring but not perfect. In the main clinical trials that led to FDA approval, cancer rates in the Prolia group and the placebo group were similar. Over three years of follow-up, roughly 1 to 2 percent of people in each group developed cancer. The numbers were small, and the difference was not statistically significant—meaning it could easily have happened by chance.

What the clinical trials actually showed

The largest and longest trial of Prolia for osteoporosis followed about 7,800 women for three years. Researchers counted every cancer diagnosis in both the Prolia group and the placebo group. The result: 23 cancers in the Prolia group, 10 in the placebo group. That difference sounds alarming until you do the math. With roughly 3,900 women in each arm, that is about 0.6 percent in the Prolia group versus 0.3 percent in the placebo group—a small absolute difference that could easily be due to chance, especially in a study of this size.

Importantly, the cancers that appeared were not clustered in one type. They were spread across different organs and tissues. If Prolia caused cancer, you would expect to see a specific pattern—more lung cancers, or more breast cancers, or more of one type. Instead, the cases were scattered, which is what you see when you are looking at random variation in a large group.

Since then, researchers have followed Prolia users for longer periods. A study published in 2019 tracked patients for up to 10 years. Again, cancer rates were not elevated compared to what you would expect in a similar population not taking the drug. This longer follow-up is important because some cancers take years to develop, so a three-year trial might miss a delayed effect.

Why some people still worry about Prolia and cancer

The concern persists partly because Prolia is not the only drug that blocks RANKL. A related drug called Xgeva (also denosumab, but given as a higher dose for cancer patients with bone metastases) has been studied in people who already have cancer. In those trials, some patients developed new cancers while on the drug. However, these were people with advanced cancer already—a very different population from someone taking Prolia for osteoporosis. You cannot directly compare cancer rates in someone with metastatic disease to someone with healthy bones.

Another reason the question lingers is that osteoporosis itself is more common in older adults, and older adults develop cancer more often simply because of age. When you give a drug to millions of older people, some will inevitably develop cancer. The question is whether the rate is higher than it would be without the drug. The evidence says it is not.

Social media and online forums sometimes amplify anecdotes—stories of individual people who took Prolia and later developed cancer. These stories are real and deserve compassion, but they do not tell you whether the drug caused the cancer or whether cancer would have developed anyway. One person's experience cannot answer that question. That is why we need large trials and long-term follow-up data, which we have.

What happens to your immune system on Prolia

Blocking RANKL does change immune function in measurable ways. Studies show that certain white blood cell counts shift slightly in people taking Prolia. However, these changes are modest and do not appear to make people more prone to infections or other immune-related problems. In clinical trials, infection rates were similar between Prolia users and placebo users.

The immune system is complex, and blocking one pathway does not shut down the whole system. Your body has many overlapping ways to fight infection and detect abnormal cells. Prolia interferes with one of them, but the others remain intact. This is why the theoretical concern did not translate into a real problem in practice.

What you should do if you take Prolia

If your doctor prescribed Prolia for osteoporosis, the current evidence does not support stopping it because of cancer worry. The benefit of preventing fractures—which can be serious, especially in older adults—is clear and well-established. The cancer risk, if it exists at all, is not detectable in the data we have.

What you should do is follow standard cancer screening guidelines for your age and sex. This means mammograms if you are a woman over 40 or 50 (depending on current guidelines), colonoscopy starting at 50, and other screening tests your doctor recommends. These are the same screenings you should have whether or not you take Prolia. There is no evidence that Prolia users need more frequent or different screening.

Tell your doctor about any new symptoms—persistent pain, unusual lumps, bleeding, or weight loss—just as you would whether or not you were taking Prolia. These are not specific to Prolia; they are signs to report for any reason.

Other side effects of Prolia that matter more

While cancer risk appears low, Prolia does carry other side effects that are more common and more relevant to most users. The most important is osteonecrosis of the jaw—a rare condition where bone in the jaw dies and does not heal properly. This is uncommon but serious, and it happens more often in people who have had dental work or have poor dental health. Before starting Prolia, your dentist should examine your teeth and gums.

Atypical fractures—breaks in the thighbone that occur in unusual places—have also been reported in people on long-term Prolia, though this is rare. Severe low blood calcium can occur, especially if you do not get enough vitamin D and calcium. These are the side effects your doctor should discuss with you, and they are more likely to affect your decision about whether to take the drug than the theoretical cancer risk.

Frequently Asked Questions

Does Prolia cause breast cancer?

No specific link between Prolia and breast cancer has been found. In clinical trials, breast cancer rates were similar in Prolia users and placebo users. If you have a personal or family history of breast cancer, discuss this with your doctor, but it is not a reason to avoid Prolia if you need it for osteoporosis.

What if I develop cancer while taking Prolia?

Developing cancer while on any medication does not mean the medication caused it. Cancer has many causes, and most develop over years or decades. Tell your oncologist that you take Prolia so they can factor it into your treatment plan, but do not assume the drug is responsible.

How long does Prolia stay in your body?

Prolia is given as an injection every six months. It has a half-life of about 26 days, meaning half the drug is cleared from your body in that time. After you stop taking it, the drug is mostly gone within a few months, though its effects on bone can last longer.

Should I get extra cancer screening if I take Prolia?

No. Standard cancer screening for your age and sex is appropriate. There is no evidence that Prolia users need more frequent mammograms, colonoscopies, or other screening tests than anyone else.

Is Prolia safer than other osteoporosis drugs?

Different osteoporosis drugs work in different ways and carry different side effect profiles. Prolia is not inherently safer or more dangerous than bisphosphonates (like alendronate) or other options. Your doctor can help you weigh the pros and cons based on your individual situation.